-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Viridian Therapeutics, Inc.\DE quarterly/annual Nonoperating Income (Expense) history and growth rate from 2016 to 2023.
- Viridian Therapeutics, Inc.\DE Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $7.19M, a 70.8% increase year-over-year.
- Viridian Therapeutics, Inc.\DE Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $22.7M, a 79.1% increase year-over-year.
- Viridian Therapeutics, Inc.\DE annual Nonoperating Income (Expense) for 2023 was $16.7M, a 277% increase from 2022.
- Viridian Therapeutics, Inc.\DE annual Nonoperating Income (Expense) for 2022 was $4.43M, a 1306% increase from 2021.
- Viridian Therapeutics, Inc.\DE annual Nonoperating Income (Expense) for 2021 was $315K, a 82.1% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)